We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Health-related quality-of-life results from multinational clinical trials of insulin lispro. Assessing benefits of a new diabetes therapy.
- Authors
Kotsanos JG; Vignati L; Huster W; Andrejasich C; Boggs MB; Jacobson AM; Marrero D; Mathias SD; Patrick D; Zalani S; Anderson J; Kotsanos, J G; Vignati, L; Huster, W; Andrejasich, C; Boggs, M B; Jacobson, A M; Marrero, D; Mathias, S D; Patrick, D
- Abstract
<bold>Objective: </bold>To compare health-related quality of life (HRQOL) in patients with diabetes receiving insulin lispro with patients receiving regular human insulin (Humulin R).<bold>Research Design and Methods: </bold>We performed two randomized comparative studies over a 6-month period (3 months per treatment). Primary analyses used crossover baseline to 3-month changes in HRQOL scores. Ninety-three principal investigators in Canada, France, Germany, and the U.S. participated in these studies. One HRQOL crossover study included 468 patients with type I diabetes; the other HRQOL crossover study included 474 patients with type II diabetes. In both studies, patients were taking insulin at least 2 months before enrollment. Primary outcomes included two generic HRQOL domains, energy/fatigue and health distress, and two diabetes-specific domains, treatment satisfaction and treatment flexibility. Thirty secondary outcomes included both generic and diabetes-specific measures. Secondary outcome domains were controlled for multiplicity in the analyses.<bold>Results: </bold>Primary analyses showed that treatment satisfaction scores (P < 0.001) and treatment flexibility scores (P = 0.001) were higher for insulin lispro in type I diabetic patients. No other significant treatment differences were detected using the data from these 6-month crossover studies.<bold>Conclusions: </bold>Treatment satisfaction and treatment flexibility were significantly improved in patients with type I diabetes using insulin lispro. Other HRQOL findings were comparable for insulin lispro and regular human insulin. Insulin lispro appears to have a measurable impact on lifestyle benefits in patients with type I diabetes, as demonstrated by increased treatment satisfaction and treatment flexibility.
- Publication
Diabetes Care, 1997, Vol 20, Issue 6, p948
- ISSN
0149-5992
- Publication type
journal article
- DOI
10.2337/diacare.20.6.948